<DOC>
	<DOCNO>NCT01466842</DOCNO>
	<brief_summary>The purpose study determine whether catheter ablation effective antiarrhythmic drug early stage paroxysmal atrial fibrillation . In patient subcutaneous loop recorder implant .</brief_summary>
	<brief_title>Ablation First Line Treatment Paroxysmal Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<criteria>Age 18 65 At least three episode paroxysmal atrial fibrillation document electrocardiogram event record last three year Never take antiarrhythmic drug pill pocket approach Willingness , ability commitment participate baseline followup evaluation Paroxysmal AF three year An episode atrial fibrillation last seven day within past six month Persistent/permanent atrial fibrillation Atrial fibrillation reversible cause ( i.e . surgery , hyperthyroidism , pericarditis ) Documented atrial flutter Structural heart disease clinical significance include : Cardiac surgery within six month screen Unstable symptom congestive heart failure ( CHF ) include NYHA Class III IV CHF screen and/or ejection fraction &lt; 30 % measure echocardiography catheterization Unstable angina Myocardial infarction within six month screen Surgically correct atrial septal defect patch closure device LA size &gt; 40mm Any prior ablation pulmonary vein Enrollment ongoing protocol Untreatable allergy contrast medium Pregnancy Any contraindication cardiac catheterization Prosthetic mitral heart valve Poor general health , opinion Investigator , allow patient good study candidate ( i.e . disease process , mental capacity , etc . ) Contraindication coumadin heparin History pulmonary embolus stroke within one year screen Acute pulmonary edema Atrial clot TEE regardless patient 's anticoagulation medication status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>